MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-Cisplatin chemotherapy in patients with non-small-cell lung cancer

Respiration

Volumn 78, Issue 1, 2009, Pages 49-55

  Pan, Ji Hong ^a   Han, Jin Xiang ^a   Wu, Jian Mei ^a   Huang, Hai Nan ^a   Yu, Qing Zhong ^a   Sheng, Li Jun ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Docetaxel; Multidrug resistance gene 1; Non small cell lung cancer; Polymerase chain reaction restriction fragment length polymorphism; Single nucleotide polymorphism

Indexed keywords

CISPLATIN; DOCETAXEL; GLYCOPROTEIN P;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DRUG RESPONSE; EXON; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TAXOIDS;

EID: 67749096078     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000158454     Document Type: Article

References (30)

1. Wakelee H, Belani CP: Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005; 10(suppl 3):1-10.
2. Thomas P, Robinet G, Gouva S, Fournel P, Lena H, Le Caer H, Perol M, Berard H, Bom-baron P, Vergnenegre A, Kleisbauer JP; Groupe français de pneumo-cancérologie. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/ docetaxel in advanced non-small cell lung cancer GFPC 99-01 study (Groupe fran-çais de pneumo-cancérologie) . Lung Cancer 2006;51: 105-114.
3. Evans WE, Relling MV: Phamacogenomics: translating functional genomics into rational t herapeutics. Science 1999; 286: 487-491.
4. Eichelaum M, Fromm MF, Schwab M: Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004; 26:180- 185.
5. Woodahl EL, Ho RJ: The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and fu nction. Curr Drug Metab 20 04,5: 11-1 9.
6. Sakaeda T, Nakamura T, Okumura K: Phar-macogenetics of MDR1 and its impact on the pharmacokinetics of drugs. Pharmacoge-nomics 2003;4: 397-410.
7. Ieiri I, Takane H, Otsubo K: The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004; 43: 553-576.
8. Woodahl EL, Ho RJ: The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and fu nction. Curr Drug Metab 2004; 5: 11-19.
9. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297: 1137-1143.
10. Patel VA, Dunn MJ, Sorokin A: Regulation of MDR-1 (P-glycoprotein) by cyclooxygen-ase-2. J Biol Chem 2002; 277: 38915-38920.
11. Brooks T, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baerand MR, Bernacki RJ: Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, mul-tidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2003; 2: 1195 -1205.
12. Shirakawa K, Takara K, Tanigawara Y, Aoya-ma N, Kasuga M, Komada F, Sakaeda T, Okumura K: Interaction of docetaxel ('Tax-otere') with human P-glycoprotein. Jpn J Cancer Res 1999; 90: 1380-1386.
13. Oselin K, Gerloff T, Mrozikiewicz PM, Pah-kla R, Roots I: MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 eff lux in peripheral blood lymphocytes. Fundam Clin Pharmacol 2003; 17: 463-469.
14. Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A: Predicting chemotherapy response to paclitax-el-based therapy in advanced non-small-cell lung cancer with p-glycoprotein expression. Respiration 2003;70: 32-35.
15. Wang D, Johhson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, A BCB1) varia nt 3435C> T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693-704.
16. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Ger-loff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one al-lele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
17. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K: Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ri-bonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71: 297-303.
18. Siegmund W, Ludwig K, Giessmann T, Da-zert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572-583.
19. Goto M, Masuda S, Saito H, Uemoto S, Kiu-chi T, Tanaka K, Inui K: C3435T polymorphism in the MDR1 gene affects the entero-cyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12:451- 457.
20. Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M: Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glyco-protein expression in human liver. Br J Clin Pharmacol 2005; 59:365-370.
21. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, Inui K: CYP3A5*1 -carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14: 471- 478.
22. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Rothen-pie le r U, Ker b R, Hof f me ye r S, Br auch H: Association of the P-glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13:1847-1854.
23. Hitzl M, Schaeffeler E, Hocher B, Slowinski T, Halle H, Eichelbaum M, Kaufmann P, Fritz P, Fromm MF, Schwab M: Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 2004; 14: 309- 318.
24. Meissner K, Jedlitschky G, Meyer zu Schwabedissen H, Dazert P, Eckel L, Vogel-gesang S, Warzok RW, Bohm M, Lehmann C, Wendt M, Cascorbi I, Kroemer HK: Modulation of multidrug resistance P-glycopro-tein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacoge-netics 2004; 14: 381-385.
25. Owen A, Chandler B, Bray PG, Ward SA, Hart CA, Back DJ, Khoo SH: Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol 2004; 78: 12022-12029.
26. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schakel U, Ehninger G, Schaich M: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002; 62:4955-4962.
27. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189- 199.
28. Puisset F, Chatelut E, Dalenc F, Busi F, Cres-teil T, Azéma J, Poublanc M, Hennebelle I, Lafont T, Chevreau C, Roche H: Dexametha-sone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004; 54:265- 272.
29. Tran A, Jullien V, Alexandre J, Rey E, Rabil-lon F, Girre V, Dieras V, Pons G, Goldwasser F, Treluyer JM: Pharmacokinetics and toxic-ity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006; 79: 570-580.
30. Synold TW, Dussault I, Forman BM: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nature Med 2001; 7:584-590.